235 related articles for article (PubMed ID: 33799527)
1. Immunogenic Cell Death by the Novel Topoisomerase I Inhibitor TLC388 Enhances the Therapeutic Efficacy of Radiotherapy.
Huang KC; Chiang SF; Yang PC; Ke TW; Chen TW; Hu CH; Huang YW; Chang HY; Chen WT; Chao KSC
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33799527
[TBL] [Abstract][Full Text] [Related]
2. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
3. Upregulation of tumor PD-L1 by neoadjuvant chemoradiotherapy (neoCRT) confers improved survival in patients with lymph node metastasis of locally advanced rectal cancers.
Chiang SF; Huang CY; Ke TW; Chen TW; Lan YC; You YS; Chen WT; Chao KSC
Cancer Immunol Immunother; 2019 Feb; 68(2):283-296. PubMed ID: 30448924
[TBL] [Abstract][Full Text] [Related]
4. Cytosolic high-mobility group box protein 1 (HMGB1) and/or PD-1+ TILs in the tumor microenvironment may be contributing prognostic biomarkers for patients with locally advanced rectal cancer who have undergone neoadjuvant chemoradiotherapy.
Huang CY; Chiang SF; Ke TW; Chen TW; Lan YC; You YS; Shiau AC; Chen WT; Chao KSC
Cancer Immunol Immunother; 2018 Apr; 67(4):551-562. PubMed ID: 29270668
[TBL] [Abstract][Full Text] [Related]
5. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
[No Abstract] [Full Text] [Related]
6. Programmed death-ligand 1 and mammalian target of rapamycin signaling pathway in locally advanced rectal cancer.
Feng Y; Luo J; Liu P; Zhu Y; Cheng G; Zheng L; Liu L
Discov Oncol; 2022 Feb; 13(1):10. PubMed ID: 35201501
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
8. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
9. Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
Machackova T; Trachtova K; Prochazka V; Grolich T; Farkasova M; Fiala L; Sefr R; Kiss I; Skrovina M; Dosoudil M; Berindan-Neagoe I; Svoboda M; Slaby O; Kala Z
Cancer Genomics Proteomics; 2020; 17(3):249-257. PubMed ID: 32345666
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of risk factors of distant metastasis in rectal cancer patients who received total mesorectal excision following neoadjuvant chemoradiotherapy].
Sun Y; Chi P; Lin H; Lu X; Huang Y; Xu Z; Huang S; Ye D; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Apr; 19(4):436-41. PubMed ID: 27112480
[TBL] [Abstract][Full Text] [Related]
11. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
Masi G; Vivaldi C; Fornaro L; Lonardi S; Buccianti P; Sainato A; Marcucci L; Martignetti A; Luca Urso ED; Castagna M; Fontanini G; Bergamo F; Musettini G; Urbani L; Sensi E; Balestri R; Montrone S; Pasqualetti F; Cremolini C; Di Paolo A; Zagonel V; Falcone A
Eur J Cancer; 2019 Mar; 110():32-41. PubMed ID: 30739838
[TBL] [Abstract][Full Text] [Related]
12. HMGB1 promotes ERK-mediated mitochondrial Drp1 phosphorylation for chemoresistance through RAGE in colorectal cancer.
Huang CY; Chiang SF; Chen WT; Ke TW; Chen TW; You YS; Lin CY; Chao KSC; Huang CY
Cell Death Dis; 2018 Sep; 9(10):1004. PubMed ID: 30258050
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide RNAi Screening Identifies RFC4 as a Factor That Mediates Radioresistance in Colorectal Cancer by Facilitating Nonhomologous End Joining Repair.
Wang XC; Yue X; Zhang RX; Liu TY; Pan ZZ; Yang MJ; Lu ZH; Wang ZY; Peng JH; Le LY; Wang GY; Peng QH; Meng Y; Huang W; Liu RY
Clin Cancer Res; 2019 Jul; 25(14):4567-4579. PubMed ID: 30979744
[TBL] [Abstract][Full Text] [Related]
14. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity.
Wang Z; Chen J; Hu J; Zhang H; Xu F; He W; Wang X; Li M; Lu W; Zeng G; Zhou P; Huang P; Chen S; Li W; Xia LP; Xia X
J Clin Invest; 2019 Aug; 129(11):4850-4862. PubMed ID: 31408442
[TBL] [Abstract][Full Text] [Related]
15. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
16. Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer.
Bains SJ; Abrahamsson H; Flatmark K; Dueland S; Hole KH; Seierstad T; Redalen KR; Meltzer S; Ree AH
Cancer Immunol Immunother; 2020 Mar; 69(3):355-364. PubMed ID: 31893287
[TBL] [Abstract][Full Text] [Related]
17. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis.
An X; Lin X; Wang FH; Goodman K; Cai PQ; Kong LH; Fang YJ; Gao YH; Lin JZ; Wan DS; Pan ZZ; Ding PR
Eur J Cancer; 2013 Mar; 49(4):843-51. PubMed ID: 23063351
[TBL] [Abstract][Full Text] [Related]
18. Pyroptotic and Necroptotic Cell Death in the Tumor Microenvironment and Their Potential to Stimulate Anti-Tumor Immune Responses.
Scarpitta A; Hacker UT; Büning H; Boyer O; Adriouch S
Front Oncol; 2021; 11():731598. PubMed ID: 34490126
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Neoadjuvant Rectal Scores in Preoperative Short-Course Radiotherapy and Long-Course Concurrent Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer.
Huang WS; Kuan FC; Lin MH; Chen MF; Chen WC
Ann Surg Oncol; 2020 Oct; 27(11):4309-4318. PubMed ID: 32794029
[TBL] [Abstract][Full Text] [Related]
20. Surgical treatment following neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Huang MY; Huang CW; Wang JY
Kaohsiung J Med Sci; 2020 Mar; 36(3):152-159. PubMed ID: 31814296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
